Michelle J Pena

Publication Activity (10 Years)

Years Active: 2017-2020
Publications (10 Years): 6

Top Topics

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Sunil B Nagaraj, Michelle J Pena, Wenjun Ju, Hiddo J Lambers Heerspink, null null
Machine-learning-based early prediction of end-stage renal disease in patients with diabetic kidney disease using clinical trials data. Diabetes, obesity & metabolism 22 (12) (2020)
Skander Mulder, Hiddo J Lambers Heerspink, Manjula Darshi, Jiwan J Kim, Gozewijn D Laverman, Kumar Sharma, Michelle J Pena
Effects of dapagliflozin on urinary metabolites in people with type 2 diabetes. Diabetes, obesity & metabolism 21 (11) (2019)
Jeroen K de Vries, Adeera Levin, Fiona Loud, Amanda Adler, Gert Mayer, Michelle J Pena
Implementing personalized medicine in diabetic kidney disease: Stakeholders' perspectives. Diabetes, obesity & metabolism (2019)
Ellen M Apperloo, Michelle J Pena, Dick de Zeeuw, Petra Denig, Hiddo J Lambers Heerspink
Individual variability in response to renin angiotensin aldosterone system inhibition predicts cardiovascular outcome in patients with type 2 diabetes: A primary care cohort study. Diabetes, obesity & metabolism 20 (6) (2018)
Nienke M A Idzerda, Frederik Persson, Michelle J Pena, Barry M Brenner, Patrick Brunel, Nish Chaturvedi, John Joseph Valentine McMurray, Hans-Henrik Parving, Dick de Zeeuw, Hiddo J Lambers Heerspink
N-terminal pro-brain natriuretic peptide (NT-proBNP) predicts the cardio-renal response to aliskiren in patients with type 2 diabetes at high renal and cardiovascular risk. Diabetes, obesity & metabolism 20 (12) (2018)
Michelle J Pena, Dick de Zeeuw, Dennis Andress, John J Brennan, Ricardo Correa-Rotter, Blai Coll, Donald E Kohan, Hirofumi Makino, Vlado Perkovic, Giuseppe Remuzzi, Sheldon W Tobe, Robert Toto, Hans-Henrik Parving, Shoba Sharma, Tom Corringham, Kumar Sharma, Hiddo J L Heerspink
The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes, obesity & metabolism 19 (5) (2017)